Actinium's initial Phase III data adds to radiopharma buzz, says analyst

An abstract published by Actinium Pharmaceuticals (NYSE: ATNM) in advance of the American Society of Hematology (ASH) meeting in December indicates dramatic results for Iomab-B in from the preliminary safety and feasibility readout from its on-going SIERRA pivotal Phase III trial in R/R AML (relapsed/refractory acute myeloid leukemia), comments Dr Chris Redhead, an analyst at Goetzpartners.

While 88% of patients in the control arm failed to achieve a complete response, 100% of patients receiving Iomab-B targeted conditioning, including all 65% of those crossed-over from the control arm, were successfully grafted with bone marrow transplant. With few effective treatment options and patients without transplant surviving for less than six months, these results provide real hope for these R/R AML patients. With further DMC and efficacy reviews for the trial anticipated early 2019E, these preliminary results indicate that Iomab-B could open the door to potentially curative bone marrow transplantation.

“With a host of additional blood cancer programs from the company's Actimab platform moving through the clinic, we reiterate our OUTPERFORM recommendation and $4.00 target price,” said Dr Redhead.